Calidi Biotherapeutics Stock Price, News & Analysis

CALIDI BIOTHERPUTICS WTS (trading under the symbol CLDWW) represents warrants related to Calidi Biotherapeutics, Inc., a company that files reports with the U.S. Securities and Exchange Commission under the name Calidi Biotherapeutics, Inc. According to multiple Form 8-K filings, Calidi Biotherapeutics, Inc. has common stock listed on the NYSE American LLC under the trading symbol CLDI, with a par value of $0.0001 per share. The warrants represented by CLDWW are a separate security linked to this underlying issuer.

In its SEC filings, Calidi Biotherapeutics, Inc. identifies itself as a registrant with a reporting telephone number in the 858 area code and indicates that there is no former name or former address change noted in the recent 8-Ks. The filings consistently present Calidi Biotherapeutics, Inc. as the company associated with the CLDI common stock and related securities such as the warrants represented by CLDWW.

The company uses Form 8-K filings to report a variety of corporate and financial developments. For example, it has reported results of operations and financial condition under Item 2.02, including the announcement of financial results for a third quarter and discussion of recent corporate developments, with related information furnished as press release exhibits. These filings clarify that such information is furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not automatically incorporated by reference into other Securities Act or Exchange Act filings unless specifically stated.

Calidi Biotherapeutics, Inc. also uses Form 8-K to provide Regulation FD disclosures under Item 7.01. In one filing, the company describes presenting new data on its first therapeutic candidate from its RedTail platform, identified as CLD-401, at the Society of Immunotherapy for Cancer Annual Meeting. The company furnished a webinar presentation and a poster as exhibits, and later issued a press release announcing the presentation of this new data. In another filing, the company notes that it made an updated corporate presentation available and issued a press release announcing the establishment of a new scientific advisory board to further develop its RedTail platform and advance CLD-401 into the clinic.

Under Item 1.01 of Form 8-K, Calidi Biotherapeutics, Inc. has reported entering into material definitive agreements. One such agreement is a Stock Repurchase Agreement with its then majority-owned subsidiary, Nova Cell, Inc., along with a Material Purchase Agreement. Through these agreements, the company sold and transferred shares of Nova Cell common stock, representing its entire ownership in Nova Cell, for a specified purchase price structured through cancellation of indebtedness and deferred consideration, along with an ongoing royalty on certain covered gross revenue. Following the closing of this transaction, Nova Cell is no longer a subsidiary of Calidi Biotherapeutics, Inc.

The same 8-K explains that the Material Purchase Agreement amends and supersedes an earlier Intellectual Property Assignment Agreement and, together with a Bill of Sale, provides for the sale and transfer to Nova Cell of certain purchased materials, subject to limitations and third-party rights. Nova Cell assumed defined liabilities and agreed to a prohibited use covenant, including a prohibition on any uses relating to oncolytic viruses, while Calidi Biotherapeutics, Inc. retained stocks of certain cell lines for its own use. The company also notes that the earlier Intellectual Property Assignment Agreement is no longer in effect as a result of this new arrangement.

In another Form 8-K, under Items 1.01 and 5.02, Calidi Biotherapeutics, Inc. describes the elimination of the position of Chief Legal Officer and the related termination of an employment agreement with an executive officer, in connection with cost-reduction and operating-efficiency initiatives. The filing explains that the decision was made to better align the company’s senior leadership structure with its size, stage of development, and available resources, and was not due to any disagreement on company operations, policies, or practices. The company entered into a General Release of Claims and Separation Agreement and a consulting agreement with the departing executive, outlining severance, bonus conditions tied to a corporate transaction involving Nova Cell, and consulting terms.

Across these filings, Calidi Biotherapeutics, Inc. emphasizes the distinction between information that is furnished and information that is filed for purposes of the Exchange Act, often stating that furnished materials, such as presentations, posters, and press releases, are not deemed filed or incorporated by reference unless expressly stated. This provides context for how investors might interpret the information associated with the CLDI common stock and, by extension, the CLDWW warrants.

Relationship between CLDWW and Calidi Biotherapeutics, Inc.

While the SEC excerpts provided focus on the issuer’s common stock (CLDI), they identify Calidi Biotherapeutics, Inc. as the registrant and establish that it has listed equity on NYSE American. CLDWW represents warrants that are tied to this issuer. Investors researching CLDWW are therefore typically examining a derivative security whose value is linked to the performance and corporate actions of Calidi Biotherapeutics, Inc. and its CLDI common stock, as disclosed in the company’s SEC filings.

Use of SEC Filings for Understanding CLDWW

The Form 8-K filings summarized above illustrate how Calidi Biotherapeutics, Inc. communicates:

• Financial results and recent corporate developments via press releases furnished as exhibits.
• Scientific and clinical-related updates, such as new data for CLD-401 from the RedTail platform, through presentations, posters, and related press releases.
• Strategic and structural changes, including transactions involving Nova Cell, Inc. and changes in leadership roles, through detailed Item 1.01 and Item 5.02 disclosures.

For holders or potential holders of CLDWW warrants, these disclosures help explain the underlying company’s activities, agreements, and governance decisions that may be relevant to the warrants’ long-term context.

Key Points for CLDWW Observers

• CLDWW represents warrants associated with Calidi Biotherapeutics, Inc.
• The underlying issuer’s common stock trades on NYSE American under the symbol CLDI.
• Calidi Biotherapeutics, Inc. uses Form 8-K to report financial results, scientific data presentations (including CLD-401 and the RedTail platform), corporate presentations, advisory board formation, asset and subsidiary transactions involving Nova Cell, Inc., and changes in executive positions.
• Many of these disclosures are furnished, not filed, under Regulation FD, and are not automatically incorporated into other filings without specific reference.